The program supports studies on the prevention or treatment of acute and chronic symptoms and morbidities related to cancer and its treatment. This includes the impact on the quality of life of patients and their informal caregivers. The program also supports studies of patients and their caregivers at the end of life.
News and Information
Topic Areas (more to come)
Anorexia, Cachexia, Cardiotoxicity, Caregiver Issues, Cognitive Dysfunction, Distress/Anxiety/Depression, End of Life, Fatigue, Geriatrics, Hot Flashes, Lymphedema, Medication Adherence, Mucositis, Multiple Symptoms, Musculoskeletal Symptoms, Nausea, Neuropathy, Nutrition, Oral Complications, Other Supportive Care Issues, Pain, Palliative Care, Pediatrics/Adolescents/Young Adult, Physical Functioning, Quality of Life, Skin Toxicities, Sleep Disorders, Urinary Complications
Higher Risk of Heart Failure Seen in Some Cancers
Some people who have been treated for breast cancer or lymphoma have a higher risk of developing congestive heart failure than people who haven't had cancer, results from a new study show.
The study researchers retrospectively compared heart failure rates in people who were diagnosed with breast cancer or lymphoma with those in people who did not have cancer.
Encouraging A Single Core Lab for Echocardiogram Results
This article summarizes a study funded by the NCI Division of Cancer Prevention to determine the reproducibility of cardiac safety assessments across two academic echocardiography core laboratories (ECLs), (Duke and the University of Pennsylvania), for echocardiograms (ECHOs) obtained in trials active in the community oncology setting.
While the labs had excellent internal consistency and high internal reproducibility, the algorithms across labs did not allow “pooling” of the results from the readings. These results have influenced how DCP has moved toward encouraging a single core lab for ECHO results when these results are in fact part of the primary endpoints of a study. The most recently funded cancer control studies in treatment-related cardiotoxicity are now using ECHO core labs.
Read the article